Dapt Score Calculator (Dual Antiplatelet Therapy)

What Is the DAPT Score?

The DAPT Score (Dual Antiplatelet Therapy Score) is a validated clinical decision-support tool that helps physicians determine whether patients should continue dual antiplatelet therapy beyond 12 months following percutaneous coronary intervention (PCI) with drug-eluting stent placement. Developed by Yeh RW et al. and published in JAMA in 2016, the score quantifies the net clinical benefit of extended antiplatelet therapy by weighing ischemic protection against bleeding risk across nine clinical variables. This evidence-based approach enables individualized treatment decisions that balance thrombotic and hemorrhagic complications.

The DAPT Score Formula

The total DAPT Score equals the sum of points assigned to nine independently validated predictors. The formula is expressed as:

DAPT Score = Age Points + Sum of Risk Factor Points

• Patient Age: Under 65 years = 0 pts; 65 to under 75 years = -1 pt; 75 years or older = -2 pts
• Current cigarette smoker: +1 point
• Diabetes mellitus: +1 point
• MI at index PCI presentation: +1 point
• Prior PCI or prior MI: +1 point
• Any stent diameter less than 3 mm: +1 point
• First-generation paclitaxel-eluting stent: +1 point
• CHF or LVEF below 30%: +2 points
• Saphenous vein graft PCI: +2 points

Scores range from -2 to 10. A score of 2 or higher identifies patients likely to benefit from prolonged DAPT beyond 12 months, while a score below 2 indicates that bleeding risk outweighs ischemic benefit.

Clinical Interpretation of Results

Score 2 or Above: Prolonged DAPT Beneficial

In the landmark DAPT Study, patients with scores of 2 or higher who continued thienopyridine therapy beyond one year experienced a 2.7% absolute reduction in combined myocardial infarction and stent thrombosis compared to placebo. This benefit came with a modest 0.7% increase in moderate-to-severe bleeding by GUSTO criteria, yielding a clearly favorable net clinical outcome for high-scoring patients.

Score Below 2: Standard or Shortened Duration Preferred

Patients scoring below 2 showed that bleeding events exceeded ischemic benefit with prolonged DAPT. The 2016 ACC/AHA Focused Update on Dual Antiplatelet Therapy incorporated this threshold to guide duration decisions after PCI. These patients should typically discontinue extended therapy at the 12-month mark unless specific clinical circumstances indicate otherwise.

Worked Clinical Example

A 70-year-old active smoker with diabetes presents with an acute MI and undergoes PCI with a 2.75 mm paclitaxel-eluting stent. She has no prior PCI history, no CHF, and no saphenous vein graft involvement. Score calculation: Age 65-74 (-1) + Smoker (+1) + Diabetes (+1) + MI at presentation (+1) + Stent diameter less than 3 mm (+1) + Paclitaxel-eluting stent (+1) = Total: 4 points. A score of 4 strongly supports prolonged dual antiplatelet therapy beyond 12 months, indicating that this patient's thrombotic risk profile substantially outweighs her bleeding risk over the extended treatment period.

Limitations and Complementary Tools

The DAPT Score was derived exclusively from patients who completed 12 months of DAPT without a major bleeding or ischemic event, so it should not be applied at the time of PCI or to patients who did not tolerate initial therapy. The score predates widespread adoption of newer-generation thin-strut drug-eluting stents, which carry lower thrombosis risk and may reduce the absolute ischemic benefit of prolonged antiplatelet therapy. Recent advances in stent platforms and antiplatelet pharmacotherapy continue to evolve clinical practice. For a complementary bleeding-focused assessment, clinicians can reference the PRECISE-DAPT score, which stratifies bleeding risk at the time of PCI to guide initial DAPT duration. Together, both tools support individualized antiplatelet decision-making across the continuum of post-PCI care.

Evidence Base and Validation

The DAPT Score was derived from 11,648 patients enrolled in the multicenter, randomized DAPT Study across 452 US and international sites. The study specifically evaluated patients who had completed 12 months of dual antiplatelet therapy without major adverse events. Multivariable regression modeling identified nine independent predictors of net clinical benefit, balancing ischemic protection against hemorrhagic complications. The model achieved a c-statistic of 0.70 in the derivation cohort, indicating good discriminatory performance. External validation confirmed the score's clinical utility across diverse patient populations undergoing contemporary PCI procedures, establishing it as a cornerstone tool in post-PCI management strategies.